In brief: Peplin, Bone Medical, Probiomics, BioDiem
Monday, 01 August, 2005
Peplin (ASX:PEP) has suspended its shares from the ASX's official quotation in the lead-up to an announcement.
Bone Medical (ASX:BNE) has appointed BIO-IB as financial advisors to assist with a potential capital raise targeting US institutional investors expected to take place later this year.
Taylor Collison intends to underwrite a $1 million placement of new fully paid ordinary shares in Probiomics (ASX:PCC). A total of 12,500,000 shares will be issued at $0.08 per share and the funds from the placement will be used for working capital.
BioDiem (ASXBDM) has received its second US$1 million milestone payment under its US$8m licence agreement with Akzo Nobel's Nobilon in the development of its novel intranasal flu vaccine.
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
